Valuation: VACY AS

Market Cap 89Cr 0 9.26Cr 8.12Cr 7.52Cr 6.92Cr 13Cr 891.8Cr 13Cr 90Cr 35Cr 437.05Cr 35Cr 34Cr 1.51TCr P/E 2026 *
-4.22x
P/E 2027 * -29.5x
Enterprise Value 41Cr 0 4.22Cr 3.7Cr 3.43Cr 3.16Cr 5.95Cr 406.52Cr 6.02Cr 41Cr 16Cr 199.23Cr 16Cr 16Cr 687.89Cr EV / Sales 2026 *
-
EV / Sales 2027 * 1.94x
Free-Float
56.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 01/01/2019
President 49 01/01/2017
Director of Finance/CFO 51 03/05/2021
Director TitleAgeSince
Director/Board Member 57 -
Director/Board Member 54 -
Chairman 45 23/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 9.26Cr
+1.80%-0.83%+52.79%+86.50% 5.56TCr
-0.21%+1.23%+56.05%+58.66% 5.43TCr
+0.10%+0.44%-17.09%-13.67% 2.33TCr
-0.56%-1.81%+4.76%+426.98% 2.35TCr
+0.05%+1.68%+38.71%-4.57% 2.03TCr
+3.16%+0.61%+37.73%-29.19% 1.74TCr
+1.08%+3.77%+36.92%+593.96% 1.56TCr
0.00%-2.08%+165.40%+297.92% 1.5TCr
-0.80%+0.08%+25.02%+179.51% 1.41TCr
Average +0.51%-1.07%+44.48%+177.34% 2.66TCr
Weighted average by Cap. +0.64%-1.21%+44.06%+139.60%

Financials

2026 *2027 *
Net sales - 16Cr 0 1.68Cr 1.47Cr 1.36Cr 1.26Cr 2.37Cr 161.76Cr 2.4Cr 16Cr 6.37Cr 79Cr 6.3Cr 6.17Cr 273.72Cr
Net income -21Cr -0 -2.16Cr -1.89Cr -1.75Cr -1.61Cr -3.04Cr -207.98Cr -3.08Cr -21Cr -8.19Cr -101.93Cr -8.11Cr -7.93Cr -351.93Cr -4.16Cr -0 -43.19L -37.86L -35.08L -32.28L -60.88L -42Cr -61.62L -4.19Cr -1.64Cr -20Cr -1.62Cr -1.59Cr -70Cr
Net Debt -49Cr -0 -5.04Cr -4.42Cr -4.09Cr -3.77Cr -7.1Cr -485.28Cr -7.19Cr -49Cr -19Cr -237.83Cr -19Cr -19Cr -821.17Cr -58Cr -0 -6Cr -5.26Cr -4.87Cr -4.48Cr -8.46Cr -577.71Cr -8.56Cr -58Cr -23Cr -283.13Cr -23Cr -22Cr -977.58Cr
Logo VACY AS
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.730NOK
Average target price
5.000NOK
Spread / Average Target
+83.15%

Quarterly revenue - Rate of surprise